SYMATESE GROUP ON THE WAY TO BECOME THE FRENCH LEADER IN SURGICAL AND MEDICAL AESTHETICS
We are pleased to announce that SYMATESE GROUP, after having submitted an offer to take over the shares of the company SEBBIN GROUP, obtained this Wednesday, October 25, 2023, the agreement of all the shareholders of this company to enter into the period of exclusivity within the framework of the legal recovery procedure to which SEBBIN GROUP is subject, until the outcome of this allows the effective recovery.
With this acquisition, SYMATESE has the ambition to become the French leader with international reach in the market for surgical and medical aesthetics and therapeutic indications.
The finalization of the acquisition process will require approximately 3 months, SEBBIN GROUP will then become a 100% subsidiary of SYMATESE GROUP, thus allowing a growth of our activities of approximately 50%.
Jean-Paul Gérardin, CEO of SYMATESE GROUP declares: “This acquisition, if it goes ahead, represents a very great opportunity, but also a major step in the life of the Group. It will indeed allow SYMATESE GROUP to expand its positions in the world and be present on 4 continents. Our Group will thus accelerate its growth and have more than 550 employees. Thanks to the synergies resulting from the alliance of SEBBIN GROUP and SYMATESE GROUP which reinforce our Transform Plan, we have before us an exciting new phase of development. »
Eric Perouse, President of SYMATESE GROUP adds: “Our takeover offer was accepted because we highlighted our strong knowledge of surgical and medical aesthetics, our unique technologies based on our research in therapeutic indications, and above all by recalling that we exploited the Perthese brand from Perouse Plastie, the leading brand on the French and Brazilian markets, marketed in more than 15 other countries in the world. »
About GROUPE SEBBIN
With more than 30 years of experience, the SEBBIN GROUP with its subsidiaries employs around 160 employees and is active in the manufacturing and marketing of aesthetic and reconstructive surgery implants, mainly made of silicone: breast implants which represent more than 70% activity but also other types of implants (gluteal, facial, etc.), tailor-made implants and a range of skin expanders as well as fat treatment devices. It generates 75% of its turnover from exports through 5 subsidiaries on 4 continents.
About SYMATESE GROUP
Created more than 25 years ago, SYMATESE’s activity draws on its expertise in tissue regeneration, reconstruction and delivery systems, for the benefit of doctors, patients, the medical and cosmetic industry. It is a private company which today brings together 400 employees including more than 40 researchers in the R&D departments. Our teams imagine, design and manufacture the most advanced technological solutions thanks to its four technological platforms integrating its own know-how and numerous patents: collagens, hyaluronic acid, silicone and thermoplastics in which we invest 15% annually.of our turnover. Each year, more than 25 million patients around the world benefit from its products thanks to partnerships established with more than 55 globally recognized companies, its international activity in particular with its two international subsidiaries SYMATESE LATAM in Sao Paulo, Brazil and SYMATESE SHANGHAI in Shanghai, China as well as its new activity as a Pure Player in the aesthetics market.
